« Back
Development of Tetrazole Based inhibitor against multple classes of Carbapenemases
Poster Title: Development of Tetrazole Based inhibitor against multple classes of Carbapenemases
Submitted on 22 Feb 2018
Author(s): Afroza Akhtar
Affiliations: Morsani College of Medicine, University of South Florida
This poster was presented at USF Health Research Day 2018
Poster Views: 335
View poster »

Poster Information
Abstract: Carbapenemases are the most versatile family of β-lactamases which are capable of hydrolyzing virtually all β-lactam antibiotics including carbapenem, the last resort of treatment in the clinical settings to treat bacterial infection. Previous studies have showed that tetrazole compounds can act as a potent inhibitor against extended spectrum β-lactamase CTX-M. Here we found a tetrazole compound in the active site of KPC-2 (class A carbapenemase), NDM-1(class B carbapenemase) and OXA-48(class D carbapenemase). For all those enzymes, the compound exhibit activity in microM level. This study provides both biochemical and biophysical report to show that tetrazole based inhibitors could be used as a potential scaffold to target different classes of carbapenemases in a non-covalent fashion.
Summary: This project centers on developing non-covalent β-lactamase inhibitors, which may represent a possible effort in countering bacterial resistance due to carbapenemases.
Chen et al Molecular docking and ligand specificity in fragment-based inhibitor discovery; Nat. Chem. Biol. 5: 358-364 (2009):
Derek A.; Structure-Based Design of Potent and Ligand-Efficient Inhibitors of CTX-M Class A β-Lactamase; J. Med. Chem., 2012, 55 (5), pp 2163–2172; DOI: 10.1021/jm2014138
Report abuse »
Creative Commons

Related Posters

Potential therapeutic effects of induced pluripotent stem cells on induced salivary gland cancer in experimental rats
Yasmine Alaa El-Din1, Dina Sabry2, Amal Hassan Abdelrahman3, and Safa Fathy3

A New Method for the Reliable Detection of 13C Multiplets of Fluorine Containing Compounds
Dimitris Argyropoulos, Rostislav Pol, Vladimir Mikhailenko, and Sergey Golotvin

Investigating orthogonal in vitro analytical approaches to demonstrate bioequivalence (BE) of nasal suspension formulations
Gonçalo Farias, Robert Price, William Ganley, Debbie Huck-Jones, Paul Kippax & Jagdeep Shur

The MODEL-AD consortium preclinical testing pipeline: pharmacokinetics and pharmacodynamics of prophylactic treatment with levetiracetam on the 5XFAD mouse model of Alzheimer’s Disease
SJ Sukoff Rizzo1, SK Quinney2, KD Onos1, KJ Keezer1, DR Jones2, AR Masters2, IF Metzger2, JA Meyer2, J Peters2, SC Persohn2, BR McCarthy2, AA Riley2, M Sasner1, G Howell1, H Williams1, AJ Oblak2, BL Lamb2, and PR Territo2

Validation of Factor IIa Assay for Dalteparin Sodium
Dr Amitabha De, Kiran Shah, Prajakta Ambre, Jyoti Gupta